Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGM - Delayed Quote USD

NKGen Biotech, Inc. (NKGN)

Compare
0.1510
-0.0141
(-8.54%)
At close: April 2 at 3:38:30 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for NKGN

Recent News: NKGN

View More
NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)

NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)
GlobeNewswire 8 days ago
Biotech Alert: Searches spiking for these stocks today

Biotech Alert: Searches spiking for these stocks today
TipRanks 19 days ago
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit

NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit
GlobeNewswire 20 days ago
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
GlobeNewswire 29 days ago
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
GlobeNewswire 30 days ago
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
GlobeNewswire last month
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site

NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site
GlobeNewswire last month
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease
GlobeNewswire last month
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease

NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
GlobeNewswire last month
NKGen Biotech Selected as Stalking Horse Bidder for NKMax

NKGen Biotech Selected as Stalking Horse Bidder for NKMax
GlobeNewswire 3 months ago
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel

NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel
GlobeNewswire 4 months ago
View More

Related Tickers

TVGN Tevogen Bio Holdings Inc.
1.0700
-1.83%
 
SPRC SciSparc Ltd.
0.3040
+5.96%
 
ZVSA ZyVersa Therapeutics, Inc.
0.5873
-0.03%
 
PXMD PaxMedica, Inc.
0.0002
0.00%
 
LIXT Lixte Biotechnology Holdings, Inc.
1.2200
+2.52%
 
BDRX Biodexa Pharmaceuticals Plc
1.5400
+28.33%
 
ATXI Avenue Therapeutics, Inc.
0.2621
-12.63%
 
NLSP NLS Pharmaceutics AG
1.4900
-2.61%
 
MRSN Mersana Therapeutics, Inc.
0.3399
+1.68%
 
ERNA Ernexa Therapeutics Inc.
0.1910
+3.30%